Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Furthermore, data from genome-wide mutation analysis from one patient allowed the reconstruction of a sequence of tumorigenesis of leukemia and HS lesions including the acquisition of a putatively activating KRAS frameshift deletion (p.A66fs). 31737984

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE However, the exact role of PKCι in KRAS-mediated pancreatic tumorigenesis is not fully defined. 31230347

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Our group previously identified the guanine nucleotide exchange factor ARHGEF10 in a genomic screen for genes with copy number alterations that may synergize with oncogenic KRAS to promote PDAC carcinogenesis. 31477830

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Our data highlight a pivotal role of the cooperative interaction between obesity-ensuing HFD and oncogenic KRAS in driving the heightened aerobic glycolysis during pancreatic tumorigenesis and suggest that in addition to directly targeting KRAS and aerobic glycolysis pathway, strategies to target the upstream of KRAS hyperactivation may bear important therapeutic value. 30819189

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered mouse models of the disease. 29079305

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Hyperinsulinemia is a risk factor for pancreatic cancer, but the function of insulin in carcinogenesis is unclear, so this study aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer. 30838710

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE KRAS mutation at codon 12 and the presence of MAPK/ERK pathway proteins were detected suggesting their association with tumorigenesis of adenomatoid odontogenic tumors. 30294831

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The inhibition of miR-199b stimulated NSCLC growth and metastasis, while restoration of miR-199b suppressed K-Ras mutation-driven lung tumorigenesis as well as K-Ras-mutated NSCLC growth and metastasis. miR-199b inactivated ERK and Akt pathways by targeting K-Ras, KSR2, PIK3R1, Akt1, and Rheb1. 30987652

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Moreover, we also discovered four novel putative target proteins of EGCG, including IKBKB, KRAS, WEE1 and NTRK1, which are significantly related to tumorigenesis. 30979098

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE The oncogene KRAS not only promotes the tumorigenesis of pancreatic cancers but also is required for the malignant progression and metastasis of these cancers. 30347501

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis. 29409705

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Both lung epithelial- and macrophage-secreted SPP1 drove tumor-associated inflammation, while epithelial SPP1 promoted early tumorigenesis by fostering the survival of KRAS-mutated cells. 31740923

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. 31227505

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Furthermore, the hallmark pathway enrichment analyses found the genes encompassed in the blue, yellow, and brown modules were significantly enriched in critical pathways involved in tumorigenesis and progression process, such as EMT and KRAS pathways. 31469983

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE We investigated how oncogenic KRAS regulates the expression of fibroblast growth factor 21, FGF21, a metabolic regulator that prevents obesity, and the effects of recombinant human FGF21 (rhFGF21) on pancreatic tumorigenesis. 31352001

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Here we show that Hes1 plays an essential role in the initiation and progression of KRAS-driven pancreatic tumorigenesis. 30705405

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE RET can be an essential co-driver of pancreatic tumorigenesis in conjugation with KRAS activity. 30515799

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. 31048544

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE It has become clear that the activated KRAS Proto‑Oncogene, GTPase (KRAS) oncogene plays an important role in colorectal carcinogenesis. 31638218

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. 31467540

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE We hypothesized that reactivation of the peptide gastrin collaborates with KRAS during pancreatic carcinogenesis. 31268978

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE What's more, KRAS could activate the ERK signaling pathway, which is associated with tumorigenesis. 31521891

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE KRAS seems to be directly associated with type I EC, and most studies support its early involvement in carcinogenesis. 30711927

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Our recent findings indicate that depletion of Pink1 and Prkn promotes pancreatic tumorigenesis in KRAS-driven engineered mouse models. 30252570

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE BRCA1, BRCA2, AKT1, MTOR, KRAS) and survival genes; possibly highlighting their importance in the carcinogenesis of breast. 31536958

2019